Patents by Inventor Fabrice JOURNÉ

Fabrice JOURNÉ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TYRP1, a natural miRNA sponge, and its use in managing human melanoma aggressiveness
    Patent number: 10287633
    Abstract: The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients' survival irrespective of the treatment administered.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 14, 2019
    Assignees: UNIVERSITE DE RENNES 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE PONTCHAILLOU
    Inventors: David Gilot, Marie-Dominique Galibert, Ghanem Ghanem, Fabrice Journe
  • NEW STRATEGIES FOR TREATING MELANOMA
    Publication number: 20170165240
    Abstract: The present invention relates to a p53-activating agent capable of transferring wild-type tumor protein p53 (p53) from an inactive conformation into an active conformation capable of inducing apoptosis, for use in the treatment of melanoma, wherein said p53-activating agent is administered simultaneously or sequentially with a BRAF-inhibiting agent capable of inhibiting activity of serine/threonine-protein kinase B-Raf (BRAF) comprising an activating mutation.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 15, 2017
    Applicants: Université Libre de Bruxelles, Institut Jules Bordet
    Inventors: Ghanem GHANEM, Fabrice JOURNÉ, Mohammad KRAYEM, Ahmad AWADA
  • TYRP1, A NATURAL MIRNA SPONGE, AND ITS USE IN MANAGING HUMAN MELANOMA AGGRESSIVENESS
    Publication number: 20160265063
    Abstract: The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients' survival irrespective of the treatment administered.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 15, 2016
    Inventors: David Gilot, Marie-Dominique Galibert, Ghanem Ghanem, Fabrice Journe